David W. Goodrich, Ph.D.
Professor of Oncology
Associate Dean for Postdoctoral Education
Roswell Park Cancer Institute

Evidence will be presented indicating RB1 loss drives transformation of prostate adenocarcinoma to neuroendocrine prostate cancer. This process is mediated by epigenetic reprogramming factors because inhibiting their activity reverses neuroendocrine transformation. I will discuss therapeutic implications and the wider relevance of this mechanism for therapeutic resistance to molecularly targeted therapies.